ReviewEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2017
MCR: modern colistin resistance.
Review in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- Global prevalence of mutation in theFrontiers in microbiology · 2024Pooled it
- Antimicrobial Activity of a Polymyxin A-like Compound and Characterisation of the Cognate Biosynthetic Gene Cluster Within the Genome of the ProducingAntibiotics (Basel, Switzerland) · 2026Article
- Global genomic characteristics of mobile colistin resistance mcr genes in Enterobacterales from companion animals.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Review
- Understanding Recent Developments in Colistin Resistance: Mechanisms, Clinical Implications, and Future Perspectives.Antibiotics (Basel, Switzerland) · 2025Review
- Prevalence of Colistin-ResistantMicroorganisms · 2025Review
- A Review on Colistin Resistance: An Antibiotic of Last Resort.Microorganisms · 2024Review
- First Report of Colistin-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Sporadic cloneFrontiers in cellular and infection microbiology · 2024Article
- Critical-Illness: Combined Effects of Colistin and Vasoactive Drugs: A Pilot Study.Antibiotics (Basel, Switzerland) · 2023Article
- Antibiotic Susceptibility Profiles and Resistance Mechanisms to β-Lactams and Polymyxins ofMicroorganisms · 2022Article
- Dissemination of Carbapenemases and MCR-1 Producing Gram-Negative Bacteria in Aquatic Environments in Batna, Algeria.Antibiotics (Basel, Switzerland) · 2022Article
- Occurrence of Extended Spectrum Cephalosporin-, Carbapenem- and Colistin-Resistant Gram-Negative Bacteria in Fresh Vegetables, an Increasing Human Health Concern in Algeria.Antibiotics (Basel, Switzerland) · 2022Article
- Worldwide Prevalence ofPathogens (Basel, Switzerland) · 2022Review
- High Carriage of Extended-Spectrum, Beta Lactamase-Producing, and Colistin-Resistant Enterobacteriaceae in Tibetan Outpatients with Diarrhea.Antibiotics (Basel, Switzerland) · 2022Article
- Dosing Colistimethate Every 8 h Results in Higher Plasma Concentrations of Active Colistin Than Every 12-Hourly Dosing without Increase in Nephrotoxicity: A Phase 1 Pharmacokinetics Trial in Healthy Adult Volunteers.Antibiotics (Basel, Switzerland) · 2022Article
- Molecular Characterization ofAntibiotics (Basel, Switzerland) · 2022Article
- Article
- Mobile Colistin Resistance Genetic Determinants of Non-TyphoidMicroorganisms · 2021Article
- Antimicrobial activity of extracts and fractions ofSaudi journal of biological sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, plasmid-mediated and, therefore, transferable bacterial polymyxin resistance was discovered in strains from both humans and animals. Such a trait may widely spread geographically, while simultaneously crossing microbial species barriers. This may ultimately render the "last resort" polymyxin antibiotics therapeutically useless. Colistin is currently used to treat infections caused by Gram-negative carbapenemase producers and colistin resistance may lead to practical pan-antibiotic resistance. We here analyzed the medical and diagnostic consequences of (emerging) colistin resistance and propose pathways toward adequate diagnostics for timely detection of both asymptomatic carriage and infection. Culture-based testing using chromogenic and selective media for screening clinical (and veterinary) specimens may constitute key tools for that purpose. Relevant molecular tests are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.